Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

1737 ARTÍCULOS , VIENDO DEL 1411 AL 1425

Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis

Catoire H, Dion PA, Xiong L, Amari M, Gaudet R, Girard SL, Noreau A, Gaspar C, Turecki G, Montplaisir JY, Parker JA, Rouleau GA.

Ann Neurol. 2011 Jul;70(1):170-5. doi: 10.1002/ana.22435. Epub 2011 Jun 27.

Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome

Manconi M, Ferri R, Zucconi M, Clemens S, Giarolli L, Bottasini V, Ferini-Strambi L.

Neurology. 2011 Jul 12;77(2):110-7. doi: 10.1212/WNL.0b013e3182242d91. Epub 2011 Jun 29.

[Restless legs syndrome and nocturnal leg pain : Differential diagnosis and treatment]

Hornyak M, Stiasny-Kolster K, Evers S, Happe S.

Schmerz. 2011 Sep;25(5):544-51. doi: 10.1007/s00482-011-1074-8.

Restless legs syndrome and conditions associated with metabolic dysregulation, sympathoadrenal dysfunction, and cardiovascular disease risk: a systematic review

Innes KE, Selfe TK, Agarwal P.

Sleep Med Rev. 2012 Aug;16(4):309-39. doi: 10.1016/j.smrv.2011.04.001. Epub 2011 Jul 5.

Development and validation of a subjective post sleep diary (SPSD) to assess sleep status in subjects with restless legs syndrome

Calloway M, Bharmal M, Hill-Zabala C, Allen R.

Sleep Med. 2011 Aug;12(7):704-10. doi: 10.1016/j.sleep.2010.09.020. Epub 2011 Jul 5.

Bupropion and restless legs syndrome: a randomized controlled trial

Bayard M, Bailey B, Acharya D, Ambreen F, Duggal S, Kaur T, Rahman ZU, Roller K, Tudiver F.

J Am Board Fam Med. 2011 Jul-Aug;24(4):422-8. doi: 10.3122/jabfm.2011.04.100173.

Pilot trial of onabotulinumtoxina (Botox) in moderate to severe restless legs syndrome

Agarwal P, Sia C, Vaish N, Roy-Faderman I.

Int J Neurosci. 2011 Nov;121(11):622-5. doi: 10.3109/00207454.2011.602774. Epub 2011 Aug 10.

Prevalence of restless legs syndrome in North American and Western European populations: a systematic review

Innes KE, Selfe TK, Agarwal P.

Sleep Med. 2011 Aug;12(7):623-34. doi: 10.1016/j.sleep.2010.12.018. Epub 2011 Jul 12.

Effect of pramipexole on cutaneous-silent-period parameters in patients with restless legs syndrome

Öz O, Erdoğan Ç, Yücel M, Akgün H, Kütükçü Y, Gökçil Z, Odabaşi Z.

Clin Neurophysiol. 2012 Jan;123(1):154-9. doi: 10.1016/j.clinph.2011.05.027. Epub 2011 Jul 14.

Restless legs syndrome probably due to clozapine

Chathanchirayil SJ.

Aust N Z J Psychiatry. 2011 Nov;45(11):1005-6. doi: 10.3109/00048674.2011.594949. Epub 2011 Jul 21.

Epidemiology of restless legs syndrome: a synthesis of the literature

Ohayon MM, O'Hara R, Vitiello MV.

Sleep Med Rev. 2012 Aug;16(4):283-95. doi: 10.1016/j.smrv.2011.05.002. Epub 2011 Jul 26.

Sleep disturbances in multiple sclerosis

Caminero A, Bartolomé M.

J Neurol Sci. 2011 Oct 15;309(1-2):86-91. doi: 10.1016/j.jns.2011.07.015. Epub 2011 Aug 3.

Development of a next day functioning measure to assess the impact of sleep disturbance due to restless legs syndrome: the restless legs syndrome-next day impact questionnaire

Lasch KE, Abraham L, Patrick J, Piault EC, Tully SE, Treglia M.

Sleep Med. 2011 Sep;12(8):754-61. doi: 10.1016/j.sleep.2011.03.015. Epub 2011 Aug 6.

[Restless legs syndrome and depression]

Rasmussen J, Videbech P.

Ugeskr Laeger. 2011 Aug 29;173(35):2113-7.

What's next after the exciting discovery and reassuring replications of genome-wide association studies of restless legs syndrome?

Xiong L.

Sleep Med. 2011 Sep;12(8):733-4. doi: 10.1016/j.sleep.2011.08.001. Epub 2011 Aug 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias